Anthill Innovation Award Top 100

In April 2009 Australian business journal Anthill Magazine named the Fermiscan Breast Cancer Test the most innovative product in Australia, at Anthill Magazine's inaugural Smart 100 Awards. The Smart 100 aims to identify and recognise Australia's 100 most innovative products. The top 100 were selected from 861 nominations from Anthill's readers by 1600 trusted experts in their fields.

Anthill magazine said the Fermiscan test was "A breathtaking innovation with the potential to save thousands of lives. The Fermiscan Breast Cancer Test wowed our mavens and is a worthy winner of Anthill's inaugural Smart 100 awards." The Awards process took more than six months and winners were announced at a ceremony on Thursday 9 April 2009 at Melbourne Docklands.

Fermiscan's Managing Director, David Young, said "We are particularly pleased to receive this award as it recognises not only ingenuity and innovation, but also our potential for rapid commercial growth. The Fermiscan Breast Cancer Test was ranked first among an extremely impressive field of innovations from many industries, and judged by experts recognised for their ability to select winners in business. We would like to thank Australian Anthill and everyone who participated in the awards."

In January 2008 six State finalists from across Australia travelled to New York city to promote their business's cutting edge innovation to the US market place by competing in the G'DAY USA INNOVATION SHOOTOUT competition. The Austrade event was a national showcase promoting Australia's leading research and technology companies. Fermiscan was selected to represent New South Wales. Each of the finalists, presented to a panel of judges, moderated by BUSINESS WEEK's Reena Jana, Innovation Department Editor.

Fermiscan was awarded this year's 'Innovator of the Year'. Fermiscan received a prize package which included consultation services provided by Austrade, an invitation to participate in the ANZA Technology Network Gateway to the US program 2008 and public relations services provided by DatelineMedia USA.

Fermiscan's Managing Director, David Young, said, "Today's innovation competition success is a powerful international endorsement for our technology. The quality of the companies in the competition was outstanding and it is an honour to win. The Fermiscan Test potentially offers significant benefits for women's health in the fight against breast cancer, as it is non-invasive and suitable for women of all ages. We are grateful to the New South Wales Government for selecting Fermiscan as their representative at the Innovation Shoot Out."

To view media interviews click here.

Back to top